Avasopasem manganese | CAS#435327-4-5 | dismutase mimetic

MedKoo Cat#: 563439 | Name: Avasopasem manganese

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Avasopasem manganese, also known as GC-4419; M 40419 and SC-72325A, is a superoxide dismutase mimetic drug candidate. GC4419 increases cancer cell killing with sensitization to ionizing radiation while protecting normal cells. GC4419 Enhances the Oxidation of Pharmacological Ascorbate and Its Anticancer Effects in an H₂O₂-Dependent Manner.

Chemical Structure

Avasopasem manganese

CAS#435327-40-5

Theoretical Analysis

MedKoo Cat#: 563439

Name: Avasopasem manganese

CAS#: 435327-40-5

Chemical Formula: C21H35Cl2MnN5

Exact Mass:

Molecular Weight: 483.38

Elemental Analysis: C, 52.18; H, 7.30; Cl, 14.67; Mn, 11.37; N, 14.49

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Avasopasem manganese; GC-4419; GC4419; GC 4419; M 40419; M40419; M-40419; SC 72325A; SC-72325A; SC72325A;

IUPAC/Chemical Name

(PBPY-7-11-2344'3')-dichlorido[(11S,12S,71S,72S)-2,6,8,11-tetraaza-4(2,6)-pyridina-1,7(1,2)-dicyclohexanacycloundecaphane-κ5N2,N1.4,N6,N8,N11]manganese

InChi Key

WXEMWBBXVXHEPU-NDOCQCNASA-L

InChi Code

InChI=1S/C21H35N5.2ClH.Mn/c1-3-10-20-18(8-1)22-12-13-23-19-9-2-4-11-21(19)25-15-17-7-5-6-16(26-17)14-24-20;;;/h5-7,18-25H,1-4,8-15H2;2*1H;/q;;;+2/p-2/t18-,19-,20-,21-;;;/m0.../s1

SMILES Code

Cl[Mn-5]1234(Cl)[N@@H+]([C@H]5CCCC[C@@H]5[N@H+]2CC6=CC=CC7=[N+]63)CC[N@@H+]1[C@@H]8[C@@H]([N@H+]4C7)CCCC8

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 483.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

This message contains search results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM). Do not reply directly to this message Sent On: Thu Nov 05 22:21:28 2020 Search: GC4419 11 selected items PubMed Results Items 1-11 of 11 (Display the 11 citations in PubMed) 1: Karlsson JOG, Jynge P, Ignarro LJ. May Mangafodipir or Other SOD Mimetics Contribute to Better Care in COVID-19 Patients? Antioxidants (Basel). 2020 Oct 10;9(10):971. doi: 10.3390/antiox9100971. PMID: 33050459; PMCID: PMC7601469. 2: El-Mahdy MA, Alzarie YA, Hemann C, Badary OA, Nofal S, Zweier JL. The novel SOD mimetic GC4419 increases cancer cell killing with sensitization to ionizing radiation while protecting normal cells. Free Radic Biol Med. 2020 Jul 30;160:630-642. doi: 10.1016/j.freeradbiomed.2020.07.032. Epub ahead of print. PMID: 32739595. 3: Adamietz IA. Superoxiddismutasemimetikum (GC4419) vs. Placebo zur Reduktion von schweren oralen Mukositiden infolge simultaner Radiochemotherapie mit Cisplatin bei Kopf-Hals-Tumoren: randomisierte, doppelblinde Phase-IIb-Studie [A superoxide dismutase mimetic (GC4419) vs. placebo to reduce severe oral mucositis due to concurrent radiotherapy and cisplatin for head and neck cancer: a phase-IIb randomized double-blind study]. Strahlenther Onkol. 2020 Sep;196(9):834-836. German. doi: 10.1007/s00066-020-01639-3. PMID: 32561942. 4: Anderson CM, Lee CM, Saunders DP, Curtis A, Dunlap N, Nangia C, Lee AS, Gordon SM, Kovoor P, Arevalo-Araujo R, Bar-Ad V, Peddada A, Colvett K, Miller D, Jain AK, Wheeler J, Blakaj D, Bonomi M, Agarwala SS, Garg M, Worden F, Holmlund J, Brill JM, Downs M, Sonis ST, Katz S, Buatti JM. Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer. J Clin Oncol. 2019 Dec 1;37(34):3256-3265. doi: 10.1200/JCO.19.01507. Epub 2019 Oct 16. Erratum in: J Clin Oncol. 2020 Jan 20;38(3):288. PMID: 31618127; PMCID: PMC6881100. 5: Mapuskar KA, Wen H, Holanda DG, Rastogi P, Steinbach E, Han R, Coleman MC, Attanasio M, Riley DP, Spitz DR, Allen BG, Zepeda-Orozco D. Persistent increase in mitochondrial superoxide mediates cisplatin-induced chronic kidney disease. Redox Biol. 2019 Jan;20:98-106. doi: 10.1016/j.redox.2018.09.020. Epub 2018 Sep 27. PMID: 30296702; PMCID: PMC6174865. 6: Batinic-Haberle I, Tovmasyan A, Spasojevic I. Mn Porphyrin-Based Redox-Active Drugs: Differential Effects as Cancer Therapeutics and Protectors of Normal Tissue Against Oxidative Injury. Antioxid Redox Signal. 2018 Dec 1;29(16):1691-1724. doi: 10.1089/ars.2017.7453. Epub 2018 Aug 28. PMID: 29926755; PMCID: PMC6207162. 7: Oronsky B, Goyal S, Kim MM, Cabrales P, Lybeck M, Caroen S, Oronsky N, Burbano E, Carter C, Oronsky A. A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis. Transl Oncol. 2018 Jun;11(3):771-778. doi: 10.1016/j.tranon.2018.03.014. Epub 2018 Apr 23. PMID: 29698934; PMCID: PMC5918142. 8: Heer CD, Davis AB, Riffe DB, Wagner BA, Falls KC, Allen BG, Buettner GR, Beardsley RA, Riley DP, Spitz DR. Superoxide Dismutase Mimetic GC4419 Enhances the Oxidation of Pharmacological Ascorbate and Its Anticancer Effects in an H₂O₂-Dependent Manner. Antioxidants (Basel). 2018 Jan 19;7(1):18. doi: 10.3390/antiox7010018. PMID: 29351198; PMCID: PMC5789328. 9: Anderson CM, Sonis ST, Lee CM, Adkins D, Allen BG, Sun W, Agarwala SS, Venigalla ML, Chen Y, Zhen W, Mould DR, Holmlund JT, Brill JM, Buatti JM. Phase 1b/2a Trial of the Superoxide Dismutase Mimetic GC4419 to Reduce Chemoradiotherapy-Induced Oral Mucositis in Patients With Oral Cavity or Oropharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):427-435. doi: 10.1016/j.ijrobp.2017.10.019. Epub 2017 Oct 16. PMID: 29174131; PMCID: PMC6430109. 10: Mapuskar KA, Flippo KH, Schoenfeld JD, Riley DP, Strack S, Hejleh TA, Furqan M, Monga V, Domann FE, Buatti JM, Goswami PC, Spitz DR, Allen BG. Mitochondrial Superoxide Increases Age-Associated Susceptibility of Human Dermal Fibroblasts to Radiation and Chemotherapy. Cancer Res. 2017 Sep 15;77(18):5054-5067. doi: 10.1158/0008-5472.CAN-17-0106. Epub 2017 Aug 1. PMID: 28765155; PMCID: PMC5600863. 11: Cramer-Morales K, Heer CD, Mapuskar KA, Domann FE. SOD2 targeted gene editing by CRISPR/Cas9 yields Human cells devoid of MnSOD. Free Radic Biol Med. 2015 Dec;89:379-86. doi: 10.1016/j.freeradbiomed.2015.07.017. Epub 2015 Jul 21. PMID: 26208779; PMCID: PMC4890619.